Translational psychiatry

Comparing weight loss drugs that target blood sugar control in people with mental illness

Updated

Abstract

This analysis includes nine randomized controlled trials with a total of 595 participants.

  • Participants had an average age of 37.8 years, with 55.3% being female.
  • The majority (83.9%) of participants had schizophrenia spectrum disorders.
  • The analysis evaluates the comparative risk-benefit profiles of glucagon-like peptide-1 receptor agonists for individuals with obesity and mental illness.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Competing interests: All authors have no conflicts of interest to declare concerning this study. They also declare any potential competing interests that have arisen in the last 3 years. Prof. Kishi has received speaker’s honoraria from Daiichi Sankyo, Shionogi, Eisai, Janssen, Meiji, Otsuka, Sumitomo, Takeda, Kyowa, Taisho, Boehringer Ingelheim, and Viatris and research grants from Eisai, JSPS KAKENHI (23K06998 and 25K10874), the Japan Agency for Medical Research and Development (JP22dk0307107, JP22wm0525024, 23dk0307117h0001, and 24dk0307129h0001, 256f0137005j0001, 266f0137005j0002, and 276f0137005j0003), and the Japanese Ministry of Health, Labour and Welfare (21GC1018). Dr. Ikuta has nothing to disclose. Dr. Hatano received the speaker’s honoraria from Meiji and Sumitomo, and has received Grant-in-Aid for Early-Career Scientists (23K14827). Dr. Sakuma has received speaker’s honoraria from Janssen, Kyowa, Meiji, Otsuka, Sumitomo, and Takeda and research grants from JSPS KAKENHI (19K17099 and 23K06998) and Japan Agency for Medical Research and Development (JP22dk0307107 and JP23dk0307122). Dr. Takayanagi has nothing to disclose. Prof. Suzuki has received speaker’s honoraria from Eli Lilly and Novo Nordisk. Prof. Iwata has received speaker’s honoraria from Eisai, Janssen, Meiji, Otsuka, Sumitomo, Takeda, Mitsubishi-Tanabe, and Viatris and research grants from Daiichi Sankyo, Eisai, Meiji, Otsuka, Sumitomo, Takeda, Tanabe-Mitsubishi, Grant-in-Aid for Scientific Research (B)(22H03003), and Japan Agency for Medical Research and Development (JP22wm0425008). Ethics approval and consent to participate: The current study includes a systematic review and meta-analysis based on secondary data from previously published, publicly available data. No new human or animal participants were recruited or studied directly by the authors. This study was performed in accordance with the relevant guidelines and regulations. All studies included in this systematic review and meta-analysis had received ethical approval from their respective institutional review boards, and informed consent was obtained from all participants in those original studies. Therefore, no additional ethical approval or informed consent was required for this study.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free